Chugh R et al THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY , CTOS Annual Meeting: 2023

Van Tine B et al. RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA. , CTOS Annual Meeting: 2023

Gounder M et al. Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors. , New England Journal of Medcine, 388(10): 2023,898-921

Gounder MM, Razak AA, Somaiah N, et al. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. , J Clin Oncol., 40(22): 2022,2479-2490

Jia H, Roberson D, Luo X, Kovell RC, Hartner L, Harryhill JF. Primary follicular lymphoma of the prostate presenting with elevated PSA and a PI-RADS 3 lesion on MRI: A case report. , Urol Case Rep.: 2022

Brody RM, Shimunov D, Cohen RB, et al. A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers. , Oral Oncol.: 2022

Civantos AM, Prasad A, Carey RM, Bur AM, Mady LJ, Brody RM, Rajasekaran K, Cannady SB, Hartner L, Ibrahim SA, Newman JG, Brant JA. Palliative care in metastatic head and neck cancer , Head Neck, 43(9): 2021,2764-2777

Reddy VK, Jain V, Wilson Ii RJ, Hartner LP, Diamond M, Sebro RA, Weber KL, Maki RG, Shabason JE. Adult Pleomorphic Rhabdomyosarcomas: Assessing Outcomes Associated with Radiotherapy and Chemotherapy Use in the National Cancer Database , Sarcoma, 2021: 2021,9712070

Baumann BC, Bernstein KA, DeLaney TF, Simone CB 2nd, Kolker JD, Choy E, Levin WP, Weber KL, Muniappan A, Berman AT, Staddon A, Hartner L, Van Tine B, Hirbe A, Glatstein E, Hahn SM, Nagda SN, Chen YL. Multi-institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicity , J Surg Oncol, 122(5): 2020,877-883

Chow W, Frankel P, Ruel C, Araujo DM, Milhem M, Okuno S, Hartner L, Undevia S, Staddon A. Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma , Cancer, 126(1): 2020,105-111